Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

Clinical trial NCT06993675 · RECRUITING

Trial details

NCT number: NCT06993675
Sponsor: Noffar Bar
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2025-08-21
Primary completion: 2029-08-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.